A Randomized, Double Blind, Placebo-controlled, Pharmacokinetics/Pharmacodynamics-guided, Phase I Study in Healthy Volunteers Given Escalating, Single Intravenous Doses of NI-0101 in the Absence and Then in the Presence of a Systemic Lipopolysaccharide Challenge.
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2016
Price : $35 *
At a glance
- Drugs NI 0101 (Primary)
- Indications Inflammation
- Focus Adverse reactions; First in man
- Sponsors NovImmune SA
- 05 Oct 2016 Safety, pharmacokinetic and pharmacodynamic results (n=73) published in the Clinical Pharmacology and Therapeutics.
- 02 Nov 2015 Results will be presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR), according to a Novimmune SA media release.
- 05 Aug 2014 Status changed from recruiting to completed, according to a Novimmune media release.